What are the benefits of Inotuzumab ozogamicin?

What conditions is Inotuzumab ozogamicin approved to treat?

Inotuzumab ozogamicin is a monoclonal antibody conjugate approved to treat adults with relapsed or refractory acute lymphoblastic leukemia (ALL). This treatment targets and destroys cancer cells that express the CD22 antigen [1].

How does Inotuzumab ozogamicin work?

Inotuzumab ozogamicin works by binding to the CD22 antigen on cancer cells and delivering a cytotoxic agent, calicheamicin, which destroys the cancer cells [2].

What are the benefits of Inotuzumab ozogamicin for patients with relapsed or refractory ALL?

Studies have shown that Inotuzumab ozogamicin can improve outcomes for patients with relapsed or refractory ALL, increasing complete remission rates and overall survival compared to chemotherapy alone [3]. Inotuzumab ozogamicin can also reduce the risk of disease progression and the need for subsequent intensive chemotherapy or hematopoietic stem cell transplantation.

Patent Information

Inotuzumab ozogamicin is the brand name for the drug, and its patent information is available on DrugPatentWatch.com [4].

Commonly Asked Questions

Can patients with other blood cancers or disorders use Inotuzumab ozogamicin?

Inotuzumab ozogamicin is specifically approved for the treatment of relapsed or refractory ALL. However, ongoing research may explore its potential in treating other blood cancers or disorders.

How long does it take for Inotuzumab ozogamicin to work?

The effects of Inotuzumab ozogamicin can be seen within a few weeks of treatment, but it may take several months for the full benefits to be realized.

Sources:
[1] FDA - Inotuzumab ozogamicin
[2] ScienceDirect - Inotuzumab ozogamicin
[3] N Engl J Med - Inotuzumab ozogamicin
[4] DrugPatentWatch.com - Inotuzumab ozogamicin